The Future of Metformin in the Prevention of Diabetes-Related Osteoporosis

Myat Aung 1, 2, Saba Amin 1, Azouba Gulraiz 1, Fenil R. Gandhi 1, Julio A. Pena Escobar 1, Bilal Haider Malik 1

1. Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA 2. Emergency Department, Poole Hospital, Poole, GBR

Corresponding author: Myat Aung, myataung2611@gmail.com

Abstract
As a worldwide aging population is on the rise, osteoporosis (OS) is becoming a global health burden. Therefore, many researchers and health authorities are looking into the potential prevention and treatment of OS. Although previously regarded as two separate pathological processes, diabetes (DM) and OS are now regarded as two conditions that can occur together. It is now believed that OS can develop as a complication of DM. This relationship is further evidenced through a reduction in bone mineral density in type-1 diabetes with a resulting increased risk of fracture. Although bone mineral density in type-2 diabetes mellitus is normal or increased, there is also increased fragility due to decreased bone quality. These abnormal bone qualities tend to occur through the production of reduced bone microvasculature and advanced glycation end product, AGE. Interestingly, one of the most common treatments for DM, metformin (MF), shows a promising result on the protection of diabetes and non-diabetes related bone turnover. It is believed that MF modulates its effect through the adenosine monophosphate-activated protein kinase (AMPK) pathway. Recent data regarded AMPK as a vital mediator of homeostasis. It is involved not only in glucose metabolism but also in osteogenesis. AMPK can directly influence the production of mature and good quality bone by decreasing osteoclasts, increasing osteoblast formation, and enhancing bone mineral deposition. As an activator of AMPK, MF also upregulates osteogenesis. Furthermore, MF can influence osteogenesis through a non-AMPK pathway, such as the fructose 1-6 phosphatase pathway, by reducing glucose levels. While already recognized as a safe and effective treatment for DM, this article discusses whether MF can be used for the prevention and treatment of OS.

Introduction And Background
Osteoporosis (OS) is the pathology of bone characterized by a decrease in the overall quality of the bone, which can eventually lead to an increased risk of fracture [1]. The prevalence of OS tends to increase with age. Adults over the age of 50, one-third of the female population and one-fifth of the male population is affected by an osteoporosis-related fracture [2]. It is estimated that approximately 125 million people living in Europe, India, Japan, and the USA have OS [2]. Similarly, diabetes mellitus (DM) is a global health burden affecting nearly 422 million individuals around the planet [3]. Also, the chances of acquiring DM increases with age.

Many recent published papers have started to recognize the relationship between OS and DM. Bone mineral density (BMD) in type-1 diabetes mellitus (T1DM) is decreased, subsequently leading to increased bone fragility [4-5]. BMD in type-2 DM (T2DM) is either normal [6] or elevated [5]. However, the prevalence of fractures in T2DM is also high, which might be due to multiple confounding mechanisms such as anti-diabetic medications, associated renal pathology, genetics, and hypo- or hyperglycaemic-related fall [7]. The risk of fracture in T2DM is notably higher in elderly menopausal women [8-9].

The principle treatment for T1DM, insulin, has been shown to increase the occurrence of bone fracture [8]. Many studies suggest that thiazolidinediones (TZD), such as rosiglitazone and pioglitazone, enhance osteoporotic-related fragility and hence should be avoided [8,10]. A newer oral hypoglycaemic agent, sodium-glucose transport protein 2 inhibitors, SGLT2 inhibitors, which include canagliflozin, dapagliflozin, and empagliflozin, should also be used with caution because of its unclear tendency toward fragility [8,10]. However, the most commonly used biguanide class of anti-diabetic drug, metformin (MF), has shown potential in preventing osteoporosis-related fractures [11].

MF modulates bone quality through many receptors, including adenosine monophosphate-activated protein kinase (AMPK) [12], which is of utmost importance for bone regeneration [11]. MF also inhibits advanced glycation end product (AGE), which can promote bone turnover [13]. A recent study even suggests that MF is beneficial for bone health in adult women without T2DM and obesity [14]. Since its discovery, MF has shown desirable lipid-lowering activity [10] and cardio-protective effect [15]. Its role in oncology has been steadily
 Liver kinase B1 (LKB1) is a protein kinase that has a regulatory effect on AMPK. Although the AMPK pathway acts as a regulator of metabolism, there are a few systems that control AMPK. The ratio will lead to the inhibition of the pathway depends on the AMP/ATP ratio: an increase in the AMP/ATP ratio will lead to activation while a decrease in generates energy in the form of adenosine triphosphate (ATP) to believed to be initiated by the binding of adenosine monophosphate (AMP) to one of these subunits mainly lead to many forms of isomers. Many researchers regarded AMPK as an energy sensor. AMPK contains three subunits (α, β, γ), which can lead to many forms of isomers (29). There are two α, two β, and three γ subunits (29). The pathway is believed to be initiated by the binding of adenosine monophosphate (AMP) to one of these subunits mainly to γ subunits, and also through phosphorylation, mainly of α subunit (32). Once bound and activated, AMPK generates energy in the form of adenosine triphosphate (ATP) (29,33). Therefore, the AMPK pathway depends on the AMP/ATP ratio: an increase in the AMP/ATP ratio will lead to activation while a decrease in the ratio will lead to the inhibition of the pathway (29,32-33).

Although the AMPK pathway act as a regulator of metabolism, there are a few systems that control AMPK. Liver kinase B1 (LKB1) is a protein kinase that has a regulatory effect on AMPK (32). It is also believed that MF has regulatory properties on AMPK through LKB1 (32). Another pathway that has an effect of AMPK is

**Methods**

The search terms included in this review article are "metformin", "osteoporosis", “Diabetes”, “type 2 diabetes”, “type 1 diabetes”, “Fracture”, “hepatic gluconeogenesis”, “AMPK”, “glucose-lowering agent”, “advanced glycation product”, “bone metabolism”, “osteogenesis”, “osteoblast”, “osteoclast”, “RANKL”, “PPAR”, and “Fructose 1-6 phosphatase.” The PubMed, Cochrane, Google Scholar, and University of Manchester online libraries were used to search for articles. Studies included in this paper are review articles, RCTs, systematic reviews, and meta-analyses.

**Review**

**Osteoporotic fractures and diabetes**

It has been many years since clinical researchers proved the link between DM and OS [5,8,17]. More recently, researchers are emphasizing the biochemical effect of DM on OS. An animal study suggests that diabetic condition deteriorates bone health by disturbing the trabecular bone architecture and BMD [18]. In an individual with T1DM, reduction in BMD can be observed and, therefore, it is reasonable that T1DM can lead to an increased risk of fracture [4-5]. However, in T2DM, normal or increased BMD can be observed [5-6]. Despite this fact, evidence suggests that the risk of fracture is higher in T2DM as compared to a non-diabetic patient [9,17-18]. These facts prove that more complex biochemical activities are causing the fragility, particularly in T2DM.

Hyperglycemia induces the production of reactive oxygen species (ROS) and AGE [19]. These products can cause oxidative stress leading to abnormal bone homeostasis [20]. Osteoblast, the bone-forming cells were inhibited and osteoclast stimulated by AGEs, causing increased bone turnover [21]. Osteoblasts derive from mesenchymal stem cells (MSC), which is the common ancestor of adipocytes. Osteoclasts develop from hematopoietic stem cells (HSC) [22]. With impaired glucose metabolism, an essential nuclear receptor called peroxisome proliferative activated receptor (PPARY) [10] causes an increased bone turnover by diverting MSC towards adipocytes and increases proliferation of HSC [23-24].

The bone was conventionally regarded as an organ to support the body and to protect the internal organs. More recently, researchers appreciated the endocrine activities of the skeleton [25]. Osteocalcin is a protein produced by mature osteoblast and is regarded as a marker of bone formation [25]. This protein plays an important role in glucose metabolism by enhancing insulin secretion by pancreatic B cells and increasing insulin sensitivity [25-26]. Therefore, not only does diabetes play a role in the development of osteoporosis, but bone also regulates the development of diabetes. Some complications of diabetes could indirectly lead to osteoporotic fracture. One animal studies suggest that diabetes disrupt the trabecular architecture of femoral head, therefore leading to higher chance osteoporotic fragility in diabetic rat than control [27]. Diabetes can also induce osteoporotic fragility through diabetic nephropathy [7] and non-alcoholic liver disease [27]. Also, lower limb muscle strength is much weaker in T2DM patients with osteoporosis than patients with T2DM alone [28]. One has also to consider that the fall initiated by the hypoglycaemic attack can also lead to osteoporotic fracture, especially in elderly postmenopausal T2DM women [8-9].

Another important mechanism that needs a detailed discussion is the AMPK pathway, whose relation with diabetes and osteoporosis will be later explained in the following section of this article. In short, AMPK is a signaling pathway that is an essential regulator of homeostasis and regarded as a potential target for the treatment of endocrine or metabolic disease, including DM [29]. This critical pathway, once activated, was shown to decrease osteoporotic related bone loss in ovariectomized rats [30]. This process seems to occur through the receptor activator of nuclear factor-kappa-B ligand (RANKL)-related increased osteoclast formation, which is inhibited by the AMPK pathway [30]. Many drugs can activate the AMPK pathway and, interestingly, MF is among these medications [31].

**Overview of the AMPK pathway**

Many researchers regarded AMPK as an energy sensor. AMPK contains three subunits (α, β, γ), which can lead to many forms of isomers (29). There are two α, two β, and three γ subunits (29). The pathway is believed to be initiated by the binding of adenosine monophosphate (AMP) to one of these subunits mainly to γ subunits, and also through phosphorylation, mainly of α subunit (32). Once bound and activated, AMPK generates energy in the form of adenosine triphosphate (ATP) (29,33). Therefore, the AMPK pathway depends on the AMP/ATP ratio: an increase in the AMP/ATP ratio will lead to activation while a decrease in the ratio will lead to the inhibition of the pathway (29,32-33).

Although the AMPK pathway acts as a regulator of metabolism, there are a few systems that control AMPK. Liver kinase B1 (LKB1) is a protein kinase that has a regulatory effect on AMPK [32]. It is also believed that MF has regulatory properties on AMPK through LKB1 [32]. Another pathway that has an effect of AMPK is
calmodulin-dependent protein kinase (CaMKKbeta), which activates via similar phosphorylation activity [33-34]. A more recent finding suggests some molecules can directly activate AMPK such as a small molecule numbered as A-769662 and an enzyme called 5-aminoimidazole-4-carboxamide-1-β-d-ribofuranoside (AICAR) [35]. Also, fructose-1, 6-bisphosphate can have a positive mediation effect on AMPK, which can lower liver glucose production [36].

**AMPK and osteogenesis**

As a pathway for stabilizing homeostasis, AMPK is involved in osteogenesis. Lipid-forming adipocytes and bone-forming osteoblasts have a common ancestor, mesenchymal stromal cells (MSC) [22]. Depending on the body’s signal, MSC can either differentiate into adipocytes or osteoblasts. The stimulation of AMPK can lead to the differentiation of MSC into osteoblasts, thereby increasing bone formation [12]. AMPK induces these effects through the runt-related transcription factor Runx2 [37], which is vital for the maturation of chondrocyte and healthy skeletal formation [23]. Also, the inhibition of AMPK led to a decrease in the production of alkaline phosphatase, osteocalcin, and type-1 collagen, all of which are important for good quality bone formation [38]. It is also shown that AMPK inhibition would lead to decreased cellular activity of alkaline phosphatase and Runx2 [38].

Another important regulator of osteogenesis that correlates with AMPK is peroxisome proliferator-activated receptors (PPAR). PPAR can direct MSC toward adipocytes, thereby reducing bone formation [24]. Interestingly, a few recent studies have shown that the activation of AMPK by pharmacological means can lead to decreased activity of PPAR, ultimately leading the MSC cell line toward osteoblast formation [22,24,37].

However, bone homeostasis involves not only osteoblasts but also osteoclasts. In contrast to osteoblasts, osteoclasts are bone-absorbing cells. These cells derive from hemopoietic precursor cells. An essential regulator of an osteoclast cell line is the receptor activator of the nuclear factor-kappa-β ligand (RANKL) pathway [39]. Recent studies suggest that AMPK decreases osteoclast formation by means of autophagy and the downregulation of the RANKL pathway [40-41].

As shown in Table 1, the activation of AMPK ultimately leads to increased catabolism by increasing cellular glucose uptake, fatty acid oxidation, and decreased glycogen synthesis while decreasing anabolism by reducing fatty acid, protein, and cholesterol synthesis [11,29,33]. Any activity that requires energy will tend to activate the AMPK pathway. Therefore, exercise can initiate the AMPK pathway [11].

| AMPK pathway                          |
|---------------------------------------|
| Increase catabolism                   |
| Increase cellular glucose uptake      |
| Increased fatty acid oxidation        |
| Decreased cellular storage of glycogen|
| Decreased synthesis of glycogen       |
| Decrease anabolism                    |
| Decreased fatty acid synthesis        |
| Decreased protein synthesis           |
| Decreased cholesterol synthesis       |

**TABLE 1: AMPK pathway**

The initiation of AMPK will lead to an increase in cellular catabolism and a decrease in anabolism.

AMPK=AMP activated protein kinase; AMP=adenosine monophosphate

As a regulator of metabolic activity, many researchers started to appreciate the role of AMPK and tried to target this pathway as a treatment of many metabolic diseases such as DM and OS. Many substances have been shown to have activity on AMPK [16,20,38,42]. Among them, MF, which is already being used as a first-line medication for DM, shows a positive regulation effect of AMPK [37,42-43].

**Metformin (past, present, and future)**

Metformin was created in 1922. MF has a strong relationship with guanidine, whose concentration is abundantly found in Galega Officinalis, also known in Europe as goat’s rue [44]. It is included in a biguanide group of medication (1-1 dimethyl-biguainide) [44]. After its discovery, it has shown glucose-lowering activity. Then, a French scientist, Jean Sterne, started the clinical trial for the treatment of diabetes during 1950 [44]. After showing promising results, it was authorized in the US by the 1990s for the treatment of diabetes [44]. MF is one of the most commonly utilized medications in the world. MF is also included in the
and treatment of osteoporosis and osteoporosis-related fractures. Randomized controlled trials have to be carried out to prove the efficacy and safety of MF for the prevention of this pathology. Additional research is fundamental in the future to determine whether MF can be used either alone or in combination with other anti-osteoporosis drugs. Also, the deterioration of bone microarchitecture caused by insulin deficiency can be prevented by the intake of MF [49].

**Conclusions**

Much research proves that DM can increase the prevalence of OS. However, this article demonstrates that one of the primary treatments of DM - MF - can interestingly decrease the occurrence of OS. Although the mechanism of action was previously unknown, with recent advances in medical and pharmacological technology, it is now proven that MF has a stimulatory effect on the AMPK pathway. Through this pathway, MF influences the bone homeostasis benefits. At the same time, this article shows that AMPK is involved not only in osteogenesis but also in the treatment of DM, and several modulatory mechanisms are being developed to target this essential pathway. Moreover, the AMPK-independent behavior of MF is discussed in this article; MF reduces poor quality bone formation as a result of abnormal glucose levels. Fructose 1,6-biphosphatase is also an important pathway found in hepatocytes, controlled by MF, increasing insulin activity in the body and ultimately leading to optimum osteogenesis. This article provides grounds for further research in the prevention of the global health burden and OS, and on whether MF is the future medication in the prevention of this pathology. Additional research is fundamental in the future to determine whether MF can be used either alone or in combination with other anti-osteoporosis drugs. Also, the dosage of MF is to be focused on its therapeutic effect. Ultimately, well-designed, double-blinded, randomized controlled trials have to be carried out to prove the efficacy and safety of MF for the prevention and treatment of osteoporosis and osteoporosis-related fractures.
Additional Information

Disclosures

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgements

The authors would like to thank the California Institute of Behavioral Neurosciences and Psychology.

References

1. Glaser DL, Kaplan FS: Osteoporosis: definition and clinical presentation. Spine (Phila Pa 1976). 1997, 22:12-16. 10.1097/00007632-199712151-00003
2. International Osteoporosis Foundation. The global burden of osteoporosis: a factsheet. (2017). Accessed: May 7, 2020: https://www.iofbonehealth.org/data-publications/fact-sheets/global-burden-osteoporosis.
3. World Health Organization: Global Report on Diabetes. World Health Organization, Geneva, Switzerland; 2016.
4. Shah VN, Harall KK, Shah CS, Gallo TL, Joshee P, Smell-Beepoon JK, Kohrt WM: Bone mineral density at femoral neck and lumbar spine in adults with type 1 diabetes: a meta-analysis and review of the literature. Osteoporos Int. 2017, 28:2601-2610. 10.1007/s00198-017-4097
5. Vestergaard P: Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysis. Osteoporos Int. 2007, 18:427-444. 10.1007/s00198-006-0255-4
6. Tuominen JT, Impivaara O, Puukka P, Rönnenma T: Bone mineral density in patients with type 1 and type 2 diabetes. Diabetes Care. 1999, 22:1196-1200. 10.2337/diacare.22.7.1196
7. Sturup-Linde J, Eriksson SA, Lykkeboe S, Hansberg A, Vestergaard P.: Biochemical markers of bone turnover in diabetes patients—a meta-analysis, and a methodological study on the effects of glucose on bone markers. Osteoporos Int. 2014, 25:1697-1708. 10.1007/s00198-014-2676-7
8. Schwartz AV, Sellmeyer DE, Ensrud KE, et al.: Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab. 2001, 86:52-58. 10.1210/jcem.86.1.17159
9. Bonds DE, Larson JC, Schwartz AV, et al.: Risk of fracture in women with type 2 diabetes: the Women’s Health Initiative Observational Study. J Clin Endocrinol Metab. 2006, 91:5404-5410. 10.1210/jc.2006-0614
10. Lecka-Czernik B: Diabetes, bone and glucose-lowering agents: basic biology. Diabetologia. 2017, 60:1163-1169. 10.1007/s00125-017-4269-4
11. Bahrambeigi S, Yousefi B, Rahimi M, et al.: Metformin; an old anti diabetic drug with new potentials in bone disorders. Biomed Pharmacother. 2019, 109:1593-1601. 10.1016/j.biopha.2018.11.032
12. Molinuevo MS, Schurman L, McCarthy AD, et al.: Effect of metformin on bone marrow progenitor cell differentiation: in vivo and in vitro studies. J Bone Miner Res. 2010, 25:211-221. 10.1359/jbmr.090752
13. Gonnelli S, Caffarelli C, Giordano N, Nuti R: The prevention of fragility fractures in diabetic patients. Aging Clin Exp Res. 2015, 27:115-124. 10.1007/s40220-014-0258-3
14. Blümel JE, Arteaga E, Aedo S, et al.: Metformin use is associated with a lower risk of osteoporosis in adult women independent of type 2 diabetes mellitus and obesity. REDLINC IX study. Gynecol Endocrinol. 2020, 36:421-425. 10.1080/09513590.2020.1718092
15. Chen C, Kassan A, Castañeda D, Gabani M, Choi S-K, Kassan M: Metformin prevents vascular damage in hypertension through the AMPK/ER stress pathway. Hypertens Res. 2019, 42:960-969. 10.1080/09513590.2019.1631412
16. Yu H, Zhong X, Gao P, et al.: The potential effect of metformin on cancer: an umbrella review. Front Endocrinol (Lausanne). 2019, 10:617. 10.3389/fendo.2019.00617
17. Melton LJ 3rd, Leibson CL, Achenbach SJ, Therneau TM, Kholia S: Fracture risk in type 2 diabetes: update of a population-based study. J Bone Miner Res. 2008, 23:1534-1542. 10.1359/jbmr.080523
18. Mohsin S, Kaimala S, Sunny JJ, Adephtne E, Brown EM: Type 2 diabetes mellitus increases the risk to hip fracture in postmenopausal osteoporosis by deteriorating the trabecular bone microarchitecture and bone mass. J Diabetes Res. 2019, 2019:3876957. 10.1155/2019/3876957
19. Volpe CMO, Villar-Delfino PH, Dos Anjos PMF, Nogueira-Machado JA: Cellular death, reactive oxygen species (ROS) and diabetic complications. Cell Death Dis. 2018, 9:119.
20. Yang P, Feng J, Peng Q, Liu X, Fan Z: Advanced glycation end products: potential mechanism and therapeutic target in cardiovascular complications under diabetes. Oxid Med Cell Longev. 2014, 2014:16055. 10.4161/omcl.2014.14055
21. Li Y, Wang L, Zhang M, et al.: Advanced glycation end products inhibit the osteogenic differentiation potential of adipose-derived stem cells by modulating Wnt/β-catenin signalling pathway via DNA methylation. Cell Prolif. 2020, 53:12834. 10.1111/cpr.12834
22. Seetharaman R, Mahmood A, Khatriya P, Patel D, Srivastava A.: An overview on stem cells in tissue regeneration. Curr Pharm Des. 2019, 25:2086-2098. 10.2174/13816128256661907211705
23. Ipinne N, Scholtesyck C, Culemann S, Kriène G: Adopted orphans as regulators of inflammation, immunity and skeletal homeostasis. Swiss Med Wkly. 2014, 144:14055. 10.4414/smw.2014.14055
24. Lecka-Czernik B: PPARs in bone: the role in bone cell differentiation and regulation of energy metabolism. Curr Osteoporos Rep. 2010, 8:84-90. 10.1007/s11914-010-0016-1
25. Mizokami A, Kawakubo-Yasukochi T, Hirata M: Osteocalcin and its endocrine functions. Biochem Pharmacol. 2017, 132:1-8. 10.1016/j.bcp.2017.02.001
26. Kanazawa I: Osteocalcin as a hormone regulating glucose metabolism. World J Diabetes. 2015, 6:1345-1354. 10.4239/wjd.v6i18.1345
27. Kumar R, Priyadarshi RN, Anand U: Non-alcoholic fatty liver disease: growing burden, adverse outcomes and associations. J Clin Transl Hepatol. 2020, 8:76-86. 10.14218/JCTH.2019.00051
28. Tamura H, Miyamoto T, Tamaki A, et al.: Osteoporosis complication is a risk factor for frailty in females with type 2 diabetes mellitus. J Phys Ther Sci. 2019, 31:621-624. 10.1589/jpts.31.621
29. Carling D: AMPK signalling in health and disease. Curr Opin Cell Biol. 2017, 45:51-57. 10.1016/j.jceb.2017.01.005
30. Ming W, Lu G, Xin S, et al.: Mitochondria related peptde MOTS-c suppresses ovariectomy-induced bone loss via AMPK activation. Biochem Biophys Res Commun. 2016, 476:412-419. 10.1016/j.bbrc.2016.05.135
31. Agius L, Ford BE, Chachea SS: The metformin mechanism on gluconeogenesis and AMPK activation: the met abolite perspective. Int J Mol Sci. 2020, 21:3240. 10.3390/ijms21093240
32. Xie Z, Dong Y, Scholz R, Neumann D, Zou M-H: Phosphorylation of LKB1 at serine 428 by protein kinase C-zeta is required for metformin-enhanced activation of the AMP-activated protein kinase in endothelial cells. Circulation. 2008, 117:952-962. 10.1161/CIRCUHNAHA.107.744490
33. Towler MC, Hardie DG: AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res. 2007, 100:528-541. 10.1161/RHY.000000000000256099.42690.05
34. Viollet B, Mouinier R, Leclerc J, Yaziji A, Foretz M, Andreelli F: Targeting AMP-activated protein kinase as a novel therapeutic approach for the treatment of metabolic disorders [Article in French, English]. Diabetes Metab. 2007, 33:395-402. 10.1016/j.diabete.2007.10.004
35. Kopietz F, Berggren C, Larson S, et al.: AMPK activation by A-769662 and 991 does not affect catecholamine-induced lipolysis in human adipocytes. Am J Physiol Endocrinol Metab. 2018, 315:1075-1085. 10.1152/ajpendo.00110.2018
36. Zhang CS, Hawley SA, Zong Y, et al.: Fructose-1,6-bisphosphatase and aldolase mediate glucose sensing by AMPK. Nature. 2017, 548:112-116. 10.1038/nature23275
37. Jiating L, BuyuN J, Yinzhong Z: Role of metformin on osteoblast differentiation in type 2 diabetes. Biomed Res Int. 2019, 2019:9203934. 10.1155/2019/9203954
38. Chai X, Zhang W, Chang B, et al.: GPR39 agonist TC-G 1008 promotes osteoblast differentiation and mineralization in MC3T3-E1 cells. Artif Cells Nanomed Biotechnol. 2019, 47:3569-3576. 10.1080/21691401.2019.1649270
39. Park BH, Lee NK, Lee SY: Current understanding of RANK signaling in osteoclast differentiation and maturation. Mol Cells. 2017, 40:706-715. 10.14348/molcells.2017.0225
40. Tong X, Zhang C, Wang D, et al.: Suppression of AMP-activated protein kinase reverses osteoprotegerin-induced inhibition of osteoclast differentiation by reducing autophagy. Cell Prolif. 2020, 53:e12714. 10.1111/cpr.12714
41. Tong X, Ganta RR, Liu Z: AMP-activated protein kinase (AMPK) regulates autophagy, inflammation and immunity and contributes to osteoclast differentiation and functionals. Biol Cell. 2020, [Epub ahead of print].10.1111/boc.202000008
42. Foretz M, Guigas B, Viollet B: Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. Nat Rev Endocrinol. 2019, 15:569-589. 10.1038/s41574-019-0242-2
43. Wang Y, An H, Liu T, et al.: Metformin improves mitochondrial respiratory activity through activation of AMPK. Cell Rep. 2019, 29:1511-1523. 10.1016/j.celrep.2019.09.070
44. Bailey CJ: Metformin: historical overview. Diabetologia. 2017, 60:1566-1576. 10.1007/s00125-017-4318-z
45. World Health Organization: World Health Organization Model List of Essential Medicines: 21st List 2019. World Health Organization, Geneva, Switzerland; 2019.
46. Palmer SC, Mavridis D, Niculucci A, et al.: Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes. A meta-analysis. JAMA. 2016, 316:315-324. 10.1001/jama.2016.9400
47. Hunter RW, Hughley CC, Laniter L, et al.: Metformin reduces liver glucose production by inhibition of fructose-1-6-bisphosphatase. Nat Med. 2018, 24:1395-1406. 10.1038/nmm.4159-1085-018-0159-7
48. Fullerton MD, Galic S, Marcinko K, et al.: Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin. Nat Med. 2015, 19:1649-1654. 10.1038/nm.3572
49. Stage TB, Christensen MH, Jørgensen NR, Beck-Nielsen H, Brøsen K, Gram J, Frost M: Effects of metformin, rosiglitazone and insulin on bone metabolism in patients with type 2 diabetes. Bone. 2018, 112:55-41. 10.1016/j.bone.2018.04.004
50. Tolosa MJ, Chuguransky SR, Sedlinsky C, Schurman L, McCarthy AD, Molinuevo MS, Cortizo AM: Insulin-deficient diabetes-induced bone microarchitectural alterations are associated with a decrease in the osteogenic potential of bone marrow progenitor cells: preventive effects of metformin. Diabetes Res Clin Pract. 2013, 101:177-186. 10.1016/j.diabres.2013.05.016